YOUR BODY, YOUR CURE

The Future of Healthcare





Aboutus

Biological Innovations is a leader in the research, development, and application of blood and bone marrow derived products for regenerative medicine. Our dedication to scientific excellence and innovation drives us to explore the full potential of the human body's natural healing abilities. Also providing healthcare professionals and patients with state-of-the-art solutions to enhance healing processes and improve overall quality of life.

Founded by a team of passionate experts in the field of regenerative medicine. Biological Innovations SARL has rapidly established itself as a pioneer in developing and delivering ground-breaking therapeutic products for a diverse range of clinical applications. Our expertise extends across the research, development, and manufacturing of superior quality, safe, and effective blood and bone marrow derived solutions.

We recognize the immense potential of the human body's natural healing capabilities. Our extensive research and development initiatives aim to uncover new possibilities in regenerative medicine. As well enabling healthcare professionals to leverage advanced tools for optimizing patient outcomes. Our commitment to excellence is evident in our comprehensive portfolio of scientifically backed products and services, supported by a steadfast dedication to quality, safety, and efficacy.





BIOI

BIOLOGICAL INNOVATIONS

AUTOLOGOUS CYTOKINES CONDITIONED SERUM

IDRIA S+

The autologous cytokines conditioned that serum anti-inflammatory effects promotes and tissue regeneration. With its unique glass beads coated with positively charged ions, IDRIA S+ activates monocytes to release anti- inflammatory cytokines such as IL-1Ra, IL-4, and IL-10. This simple process can produce 15 ml of serum enriched with these cytokines and a large amount of growth factors, without the need for incubation. With just 30 minutes of activation and a 10-minute spin, physicians can obtain a powerful concentration of deliverable regenerative cells to promote tissue healing.

Page 11

IDRIA S+

Autologous Cytokines Conditioned Serum includes the IDRIA S+ 30ml tube and accessories for blood draw. IDRIA S+ comprises glass beads coated with positively charged ions, which interact with monocytes to stimulate the release of inflammatory mediators, including the anti-inflammatory IL-1Ra. Processing 30 ml of whole blood with IDRIA S+ yields 15 ml of autologous serum rich in cytokines.

IDRIA S+ provides a hyper-concentration and cellular stimulation of IL-1Ra directly from the patient's own blood, eliminating the need for any incubation process.

The presence of glass beads in IDRIA S+ activates monocytes to produce anti-inflammatory cytokines such as IL-1Ra and enhances the concentration of anti-inflammatory cytokines IL-4 and IL-10.

IL-1Ra, known as interleukin-1 receptor antagonist, is a naturally occurring cytokine that inhibits inflammation by binding to the IL-1 receptor, thereby preventing its activation. IL-1Ra not only blocks IL-1 but also exhibits analgesic and neuroprotective properties. It helps maintain proteinase balance and, in synergy with IL-4 and IL-10, promotes homeostasis in the microenvironment and tissue (including cartilage) synthesis.

Following centrifugation, a serum enriched with these cytokines and a significant amount of growth factors released from platelets (TGF-β, HGF, VEGF, IGF, PDGF) can be obtained. This cell-free serum exhibits high production of IL-1Ra within just 30 minutes, without the need for incubation.

Physicians can process 30 ml of blood, wait just 30 minutes for activation, and obtain 15 ml of Autologous Conditioned Serum with high concentrations of anti-inflammatory cytokines in a single 10-minute spin (2700 rgf).

BIOLOGICAL
INNOVATIONS

High volume andNo need for incubation:Red Cells:Glass Beads:concentration ofInduce the production ofcytokinesWithin 40minsLess than 0,2%

Page 12

cytokines IL-1Ra

IDRIAS+ INDICATIONS



Osteoarthritis

These therapies are commonly used to treat osteoarthritis, a degenerative joint disease characterized by cartilage breakdown, inflammation, and pain. By reducing inflammation and modulating the immune response, these treatments can help alleviate pain and potentially slow down the degenerative process.

Rheumatoid arthritis

Rheumatoid arthritis is an autoimmune condition causing joint inflammation, pain, and potential joint deformity. While these therapies have been less commonly used for rheumatoid arthritis, they may help manage symptoms by reducing inflammation and pain.

Gynaecology

These therapies could potentially be explored for their effects on inflammatory gynaecological conditions such as endometriosis or pelvic inflammatory disease, where reducing inflammation may help alleviate symptoms.

Sports-related injuries

These treatments may be used for joint, ligament, or muscle injuries sustained during sports activities, with the aim of promoting healing, reducing inflammation, and shortening recovery times.

Post-surgical joint recovery

These therapies could be used to improve joint recovery following surgical procedures, such as arthroscopy or joint replacement, by reducing inflammation and promoting tissue repair.

Hair loss

While more commonly treated with platelet-rich plasma (PRP) therapy, it is possible that these therapies could be investigated for their potential role in promoting hair follicle health and regrowth.

Tendinopathies

Inflammatory conditions of the tendons, such as tendonitis or tendinosis, may benefit from these therapies. They could potentially reduce inflammation and promote tissue healing.

Urology

Their anti-inflammatory properties might be beneficial in the context of chronic prostatitis, interstitial cystitis, or other inflammatory urological conditions.



BIBLIOGRAPHY

- 1. Beer L, Mildner M, Gyöngyösi M, Ankersmit HJ. Peripheral blood mononuclear cell secretome for tissue repair. Apoptosis. 2016 Dec;21(12):1336-1353. doi: 10.1007/s10495-016-1292-8. PMID: 27696124; PMCID: PMC5082595.
- Lana JF, Huber SC, Purita J, Tambeli CH, Santos GS, Paulus C, Annichino-Bizzacchi JM. Leukocyte-rich PRP versus leukocyte-poor PRP The role of monocyte/macrophage function in the healing cascade. J Clin Orthop Trauma. 2019 Oct;10(Suppl 1):S7-S12. doi: 10.1016/j.jcot.2019.05.008. Epub 2019 May 13. PMID: 31700202; PMCID: PMC6823808.
- 3. Zhang M, Huang B. The multi-differentiation potential of peripheral blood mononuclear cells. Stem Cell Res Ther. 2012 Nov 30;3(6):48. doi: 10.1186/scrt139. PMID: 23200034; PMCID: PMC3580478.
- 4. Arend WP, Smith MF Jr, Janson RW, Joslin FG. IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J Immunol. 1991 Sep 1;147(5):1530-6. PMID: 1831827.
- 5. Arend WP, Leung DY. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev. 1994 Jun;139:71-8. doi: 10.1111/j.1600-065x.1994.tb00857.x. PMID: 7927414.
- Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C et al: Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 39(1996)1535–1544.
- 7. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27-55. doi: 10.1146/annurev.immunol.16.1.27. PMID: 9597123.
- 8. King W, van der Weegen W, Van Drumpt R, Soons H, Toler K, Woodell-May J. White blood cell concentration correlates with increased concentrations of IL-1ra and improvement in WOMAC pain scores in an open-label safety study of autologous protein solution. J Exp Orthop. 2016 Dec;3(1):9. doi: 10.1186/s40634-016-0043-7. Epub 2016 Feb 9. PMID: 26915009; PMCID: PMC4747972.
- Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012 Aug;11(8):633-52. doi: 10.1038/nrd3800. PMID: 22850787; PMCID: PMC3644509.
- 10. Joseph Alsousou and Paul Harrison. Therapeutic Platelet-Rich Plasma in Wound Healing. Platelets. Platelets, Academic Press, 2019, Pages 1161-1171. ISBN 9780128134566. https://doi.org/10.1016/B978-0-12-813456-6.00065-5.
- 11. Mildner M, Hacker S, Haider T, Gschwandtner M, Werba G, Barresi C, Zimmermann M, Golabi B, Tschachler E, Ankersmit HJ. Secretome of peripheral blood mononuclear cells enhances wound healing. PLoS One. 2013;8(3):e60103. doi: 10.1371/journal.pone.0060103. Epub 2013 Mar 22. PMID: 23533667; PMCID: PMC3606336.
- 12. Fréchette JP, Martineau I, Gagnon G. Platelet-rich plasmas: growth factor content and roles in wound healing. J Dent Res. 2005 May:84(5):434-9. doi: 10.1177/154405910508400507. PMID: 15840779.
- 13. Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. J Thromb Haemost. 2006 May;4(5):932-9. doi: 10.1111/j.1538-7836.2006.01861.x. PMID: 16689737.
- 14. Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM, Sokolove J. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Oct;12(10):580-92. doi: 10.1038/nrrheum.2016.136. Epub 2016 Aug 19. PMID: 27539668; PMCID: PMC5500215.
- Baselga García-Escudero J, Miguel Hernández Trillos P. Treatment of Osteoarthritis of the Knee with a Combination of Autologous Conditioned Serum and Physiotherapy: A Two-Year Observational Study. PLoS One. 2015 Dec 28;10(12):e0145551. doi: 10.1371/journal.pone.0145551. PMID: 26709697; PMCID: PMC4692499.
- Cavallo C, Filardo G, Mariani E, Kon E, Marcacci M, Pereira Ruiz MT, Facchini A, Grigolo B. Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study. J Bone Joint Surg Am. 2014 Mar 5;96(5):423-9. doi: 10.2106/JBJS.M.00726. PMID: 24599205
- 17. Woodell-May J, Matuska A, Oyster M, Welch Z, O'Shaughnessey K, Hoeppner J. Autologous protein solution inhibits MMP-13 production by IL-1β and TNFα-stimulated human articular chondrocytes. J Orthop Res. 2011 Sep;29(9):1320-6. doi: 10.1002/jor.21384. Epub 2011 Mar 15. PMID: 21437966.
- Van Drumpt RA, van der Weegen W, King W, Toler K, Macenski MM. Safety and Treatment Effectiveness of a Single Autologous Protein Solution Injection in Patients with Knee Osteoarthritis. Biores Open Access. 2016 Aug 1;5(1):261-8. doi: 10.1089/biores.2016.0014. PMID: 27668131; PMCID: PMC5031090.
- Hix J, Klaassen M, Foreman R, Cullen E, Toler K, King W, Woodell-May J. An Autologous Anti-Inflammatory Protein Solution Yielded a Favorable Safety Profile and Significant Pain Relief in an Open-Label Pilot Study of Patients with Osteoarthritis. Biores Open Access. 2017 Dec 1;6(1):151-158. doi: 10.1089/biores.2017.0027. PMID: 29279807; PMCID: PMC5738995.

BIBLIOGRAPHY

- Mifuji K, Ishikawa M, Kamei N, Tanaka R, Arita K, Mizuno H, Asahara T, Adachi N, Ochi M. Angiogenic conditioning of peripheral blood mononuclear cells promotes fracture healing. Bone Joint Res. 2017 Aug;6(8):489-498. doi: 10.1302/2046-3758.68.BJR-2016-0338.R1. PMID: 28835445; PMCID: PMC5579315.
- 21. Monckeberg JE, Rafols C, Apablaza F, Gerhard P, Rosales J. Intra-articular administration of peripheral blood stem cells with platelet-rich plasma regenerated articular cartilage and improved clinical outcomes for knee chondral lesions. Knee. 2019 Aug;26(4):824-831. doi: 10.1016/j.knee.2019.05.008. Epub 2019 Jun 18. PMID: 31227435.
- 22. Vishal Chand, Sipahee Lal Patel, Rachana Mishra, Baishnab C Tripathy, Jaya Prakash, Md. Tashfeen Ashraf and Varsha Gupta. Molecular signatures in peripheral blood mononuclear cells with osteoarthritis. Int. J. Clin. Rheumatol. (2016) 11(6), 082–091.
- 23. Loukov D, Karampatos S, Maly MR, Bowdish DME. Monocyte activation is elevated in women with knee-osteoarthritis and associated with inflammation, BMI and pain. Osteoarthritis Cartilage. 2018 Feb;26(2):255-263. doi: 10.1016/j.joca.2017.10.018. Epub 2017 Nov 8. PMID: 29128509.
- 24. Hopper N, Henson F, Brooks R, Ali E, Rushton N, Wardale J. Peripheral blood derived mononuclear cells enhance osteoarthritic human chondrocyte migration. Arthritis Res Ther. 2015 Aug 7;17(1):199. doi: 10.1186/s13075-015-0709-z. PMID: 26249339; PMCID: PMC4528856.
- 25. Darshan S. Angadi, Hamish Macdonald and Navraj Atwal. Autologous cell-free serum preparations in the management of knee osteoarthritis: what is the current clinical evidence? Surgery & Related Research (2020) 32:16.
- 26. J. Schwitzguebel, M. Bogoev, V. Nikolov, F. Ichane and A. Lädermann. Tennis elbow, study protocol for a randomized clinical trial: needling with and without platelet-rich plasma after failure of up-to-date rehabilitation. Journal of Orthopaedic Surgery and Research (2020) 15:462.
- 27. LaBelle MW, Marcus RE. CORR Synthesis: What Is the Role of Platelet-rich Plasma Injection in the Treatment of Tendon Disorders? Clin Orthop Relat Res. 2020 Aug;478(8):1817-1824. doi: 10.1097/CORR.00000000001312. PMID: 32732562; PMCID: PMC7371072.
- 28. Hastie G, Soufi M, Wilson J, Roy B. Platelet rich plasma injections for lateral epicondylitis of the elbow reduce the need for surgical intervention. J Orthop. 2018 Jan 31;15(1):239-241. doi:10.1016/j.jor.2018.01.046. PMID: 29657476; PMCID: PMC5895905.
- 29. Yi-Jun Zhang MD, San-Zhong Xu MD, Peng-Cheng Gu MD, Jing-Yu Du MD, You-Zhi Cai MD, Chi Zhang MD, Xiang-Jin Lin MD. Is Platelet-rich Plasma Injection Effective for Chronic Achilles Tendinopathy? A Meta-analysis. Clin Orthop Relat Res (2018) 476:1633-1641. DOI 10.1007/s11999.0000000000258
- 30. Liu CJ, Yu KL, Bai JB, Tian DH, Liu GL. Platelet-rich plasma injection for the treatment of chronic Achilles tendinopathy: A meta-analysis. Medicine (Baltimore). 2019 Apr;98(16):e15278. doi: 10.1097/MD.000000000015278. PMID: 31008973; PMCID: PMC6494278.
- 31. Pooja Pithadia, Sharmila S.Tulpule, Mrinalini singh & Pratham Surya. Platelet rich plasma therapy for shoulder tendinopathy: a systematic review. Int. J. Clin. Rheumatol. (2021) 16(5), 149-157.
- 32. Townsend C, Von Rickenbach KJ, Bailowitz Z, Gellhorn AC. Post-Procedure Protocols Following Platelet-Rich Plasma Injections for Tendinopathy: A Sytematic Review. PM R. 2020 Sep;12(9):904-915. doi: 10.1002/pmrj.12347. Epub 2020 Apr 6. PMID: 32103599.
- 33. Goni VG et al (2015): Efficacy of Epidural Perineural Injection of Autologous Conditioned Serum in Unilateral Cervical Radiculopathy: A Pilot Study. Spine (Phila Pa 1976) Aug2015, 15;40(16): E915-21
- 34. Goldring MB: Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep 2 (2000)
- Neidel J, Schulze M, Sova L, Lindschau J: Practical significance of cytokine determination in joint fluid in patients with arthroses or rheumatoid arthritis. Z Orthop Ihre Grenzgeb 134 (1996) 381– 385. ARTICOLO IN TEDESCO
- 36. Towle CA et al. (1997): Detection of interleukin-1 in the cartilage of patients with osteoarthritis: a possible autocrine/paracrine role in pathogenesis. Osteoarthr Cartil 5(5): 293-300

A GAME-CHANGER IN REGENERATIVE MEDICINE



BIOLOGICAL



REACH OUT TO US

www.biologicalinnovations.trade

